KPV Information & Coordination for Licensed U.S. Clinics
KPV, or lysine-proline-valine, is a tripeptide that has been discussed in research and pharmacy-compounding contexts.
FDA evaluated KPV free base and KPV acetate in 2026 as part of its process for considering bulk drug substances under section 503A of the Federal Food, Drug, and Cosmetic Act. Neither substance is a component of an FDA-approved drug.
Phoenix Meds Inc. supports licensed healthcare organizations with credential review, documentation, publicly available regulatory information, and administrative coordination.
We are not a pharmacy, medical practice, manufacturer, prescriber, or dispensing entity.
What Clinics Should Know About KPV
FDA describes KPV as a tripeptide made up of lysine, proline, and valine. The agency separately evaluated KPV free base and KPV acetate because they are different active pharmaceutical ingredients.
FDA also found inconsistencies in how KPV-related substances have been named and characterized. The agency notes that KPV is a common name rather than a United States Adopted Name and that inconsistent naming can create uncertainty about which substance is actually being referenced.
That distinction matters for clinics reviewing product documentation or regulatory information.
Phoenix does not present KPV as an FDA-approved treatment or promote it for inflammation, gastrointestinal conditions, wound healing, skin conditions, immune modulation, recovery, or other treatment outcomes.
Current FDA and Compounding Status
FDA evaluated KPV free base and KPV acetate in 2026 for possible inclusion on the section 503A Bulks List. The original nomination was withdrawn, but FDA continued evaluating both substances on its own initiative.
FDA states that neither substance has an applicable USP or National Formulary drug-substance monograph and neither is a component of an FDA-approved drug. The agency concluded that its evaluation criteria weighed against placing either substance on the 503A Bulks List and proposed that both not be included.
FDA’s advisory-committee process is not itself a final agency determination, so clinics should verify current FDA information before relying on a particular compounding pathway.
Why Product Identity Matters
FDA’s review identified uncertainty around the identity and characterization of KPV-related bulk drug substances.
The nomination FDA evaluated contained inconsistent information about whether the substance involved was KPV free base or KPV acetate. FDA treats these as separate bulk drug substances rather than interchangeable descriptions.
For clinics, that makes documentation important. A name on a product page or certificate should not be treated as enough to establish identity, regulatory status, or suitability.
Phoenix can help organize available documentation and regulatory information so the clinic can identify questions that require further review.
We do not determine clinical suitability or make a legal determination that a particular preparation may be compounded.
How Phoenix Meds Supports Licensed Clinics
Our role is administrative.
Licensed healthcare organizations may use Phoenix for help reviewing professional credentials, organizing supporting records, checking publicly available licensing and regulatory information, and identifying documentation questions that still need to be addressed.
Our support may include:
- clinic and provider credential review;
- organization of available documentation;
- review of publicly available regulatory and licensing records;
- administrative communication between professional entities; and
- identification of information that may require review by the appropriate pharmacy, clinician, regulatory professional, or legal counsel.
The purpose is to reduce administrative back-and-forth while keeping the responsibilities of each party clear.
Phoenix’s review is not FDA approval, pharmacy accreditation, a treatment recommendation, or a legal opinion.
Safety and Documentation Considerations
FDA states that it has not identified human-exposure data for drug products containing KPV administered by any route.
The agency also says it lacks important information regarding potential safety issues, including whether KPV could cause harm when administered to humans.
FDA’s 2026 review additionally identified characterization concerns involving KPV-related substances, including incomplete information about impurities, aggregation, and certain quality-control attributes.
Phoenix does not manufacture, test, compound, dispense, ship, or take custody of KPV. We also do not certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
KPV Administrative Coordination for Licensed Clinics
Licensed U.S. healthcare organizations may contact Phoenix Meds Inc. regarding credential review, documentation, and publicly available regulatory information relevant to a KPV-related inquiry. An administrative inquiry is not a medication order and does not establish product availability, compounding eligibility, FDA approval, or clinical appropriateness.
Clinic Verification
Licensed healthcare organizations may submit relevant professional and facility credentials for administrative verification.
Documentation Review
Licensed Parties
Prescribing, compounding, dispensing, distribution, storage, shipping, and other regulated medication activities remain with the parties legally authorized and responsible for performing them.
Frequently Asked Questions
Is KPV FDA approved?
FDA’s 2026 materials state that KPV free base and KPV acetate are not components of FDA-approved drugs.
Is KPV on the 503A Bulks List?
FDA evaluated KPV free base and KPV acetate in 2026 and proposed that neither be included on the 503A Bulks List. The advisory process is not itself a final agency determination, so clinics should verify the current FDA status before relying on a particular compounding pathway.
Are KPV free base and KPV acetate the same substance?
Does Phoenix Meds Inc. compound or dispense KPV?
What can Phoenix Meds help a clinic with?
Does Phoenix Meds provide KPV dosing or treatment protocols?
Does Phoenix guarantee KPV quality or safety?
No. Phoenix does not test KPV or certify its purity, potency, sterility, authenticity, safety, or clinical suitability.
Important Notice
Phoenix Meds Inc. provides administrative coordination, documentation, and compliance-focused support for licensed healthcare organizations.
We are not a pharmacy, medical practice, drug manufacturer, outsourcing facility, prescriber, or dispensing entity.
This page is intended for professional informational purposes. It does not present KPV as an FDA-approved treatment and does not establish that a particular compounding or distribution pathway is available or permitted.